Akamai Technologies has staged a sharp recovery from its post-earnings lows, yet the short interest and options data tell a more complicated story beneath the surface.
The most decisive development this week came from the Street. JP Morgan's Samik Chatterjee upgraded AKAM from Underweight to Neutral on August 13, lifting his target from $132 to $158 — a notable reversal from a bellwether firm that had been firmly in the bear camp. That move helped carry the stock up 13% on the week to $124.99, erasing much of the post-earnings damage. The broader analyst picture, however, remains cautious rather than enthusiastic. HSBC downgraded to Hold on August 10, slashing its target from $171 to $123, while Susquehanna trimmed from $175 to $140 without changing its Positive rating. RBC and Piper Sandler both cut targets while holding neutral stances. The consensus is still a Hold, with 11 analysts there and none at Underperform — but the mean target of $157 implies roughly 26% upside from current levels, suggesting the Street sees value even if it lacks conviction. Guggenheim stands out as the lone bull, raising its Buy target to $190.
The positioning picture is where the tension lives. Short interest has continued building even as the stock recovered — bears added steadily through the week, pushing SI to 14.2% of the free float, up from 13.9% a week ago and up nearly 7% over the past month. The absolute count has climbed from around 19.1 million shares in early July to just above 20.4 million now, a consistent one-way move that predates and survives the JP Morgan upgrade. That is the key tension: a stock rallying 13% on the week against a short base that refuses to cover. Borrow conditions offer no squeeze catalyst — cost to borrow is a modest 0.43% and availability is loose at 316%, meaning there are roughly three shares available to borrow for every two already shorted. Bears face no meaningful pressure to exit.
Options tell a different story from the stock's buoyant price action. The put/call ratio jumped to 0.55 on August 14, nearly three standard deviations above its 20-day average of 0.28. That is the same elevated defensive posture flagged in last week's note — it has not unwound despite the rally. The 52-week high for the PCR is 0.71, so the current reading is well into the top quartile of hedging activity for this name. Traders are still buying downside protection, even as the stock prints a fresh near-term high.
The bull case rests on Akamai's CDN dominance, a reported $1.8 billion AI-related deal, and what the factor scores describe as exceptional forward earnings momentum — the 12-month forward EPS growth rank sits at the 98th percentile of its universe. The bear case centres on execution risk in cloud computing, commoditisation pressure in legacy CDN, and a near-term revenue shortfall tied to GPU supply delays and elevated capex. The short score of 62.4 has drifted higher through August, consistent with the steady short-build rather than any imminent reversal signal.
The next earnings event is not until November 3, leaving the market with a long runway to debate whether the JP Morgan upgrade marks a genuine inflection or simply a reset after an overshooting selloff. The behaviour of the short base over the coming weeks — whether it trims into strength or continues building through $125 — will be the clearest signal of which side is gaining conviction.
See the live data behind this article on ORTEX.
Open AKAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
